To access this element change to forms mode OFF
Grant Award View - GA217920
SWiMS - Schizophrenia Weight, Metformin and Semaglutide: A double blind...
GA ID:
GA217920
Agency:
Department of Health and Aged Care
Approval Date:
6-Dec-2021
Publish Date:
16-Feb-2022
Category:
Health and Medical Research
Grant Term:
1-Feb-2022 to 31-Jan-2027
Value (AUD):
$3,839,117.60
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 21/22 1.1 Health Policy Research and Analysis
Grant Program:
MRFF Research Grants
Grant Activity:
SWiMS - Schizophrenia Weight, Metformin and Semaglutide: A double blind double dummy placebo controlled multi-centre RCT
Purpose:
Antipsychotics are the mainstay of treatment for schizophrenia. However, antipsychotics are linked with obesity and diabetes, which increase the risk of heart disease. Our preliminary research suggests that the diabetes drugs semaglutide and metformin can reduce antipsychotic-related obesity. We now propose to undertake a rigorous multi-site national clinical trial, to establish the role of semaglutide and metformin in meaningfully reducing weight among obese people taking antipsychotics.
GO ID:
GO Title:
MRFF 2021 Rare Cancers Rare Diseases Unmet Need General - Grant Opportunity
Internal Reference ID:
2021/MRF2014887
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
The University of Queensland
Recipient ABN:
63 942 912 684
Grant Recipient Location
Suburb:
St Lucia
Town/City:
St Lucia
Postcode:
4072
State/Territory:
QLD
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
QLD
Postcode:
Country:
AUSTRALIA